Theravance settles YUPELRI patent suit; generic license start April 23, 2039

Theravance Biopharma, Inc.

Settlement with Mankind Pharma resolves Hatch-Waxman litigation over YUPELRI (revefenacin) ANDA.
Royalty-free license granted for generic version on or after April 23, 2039, subject to customary exceptions.
All pending Hatch-Waxman litigation relating to YUPELRI now resolved; settlement subject to DOJ/FTC review.
Involves patents 11,484,531, 12,048,692 and 12,285,417; parties include Theravance subsidiaries and Mylan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.